Clinical Impact of New Viral Hepatitis Data From AASLD 2021*

Download All
November 12-15, 2021; Virtual
Get up to date on the latest practice-changing viral hepatitis data presented at AASLD 2021. To review key studies on HBV, HCV, and HDV, view on-demand webinars, listen to the on-demand podcast, download the slides, and read expert commentaries.
Paul Y. Kwo, MD
Nancy Reau, MD
Stefan Zeuzem, MD

Viral Hepatitis Highlights

Read expert faculty members’ summaries of HBV, HCV, and hepatitis delta virus (HDV), including data on HBV therapy during pregnancy, outcomes following treatment withdrawal in HBV, progress toward an HBV cure, HDV clinical impact and phase III clinical trial updates, and HCV implementation science and current status of the cascade of care.

Nancy Reau, MD Stefan Zeuzem, MD Released: November 29, 2021

Hepatitis delta is the most severe form of viral hepatitis and yet its diagnosis remains elusive. Read my take on why universal screening of all patients with HBV for hepatitis delta is necessary.

Paul Y. Kwo, MD Released: December 3, 2021

Listen to expert insights from Stefan Zeuzem, MD, on updates and new viral hepatitis data from AASLD 2021, including HBV treatment in pregnancy, outcomes following HBV treatment withdrawal, progress toward HBV cure, HCV implementation science and care cascades, characterization of the population with hepatitis delta, and more.

Stefan Zeuzem, MD Released: November 30, 2021

Listen to expert insights from Nancy Reau, MD, on updates and new viral hepatitis data from AASLD 2021, including HBV treatment in pregnancy, outcomes following HBV treatment withdrawal, progress toward HBV cure, HCV implementation science and care cascades, characterization of the population with hepatitis delta, and more.

Nancy Reau, MD Released: December 3, 2021

Listen to expert insights from Nancy Reau, MD, on updates and new viral hepatitis data from AASLD 2021, including HBV treatment in pregnancy, outcomes following HBV treatment withdrawal, progress toward HBV cure, HCV implementation science and the cascade of care, characterization of the population with hepatitis delta, and phase III clinical trial updates for hepatitis delta.

Nancy Reau, MD Released: December 1, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings